Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities
H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. section 28a of the Danish Securities Trading Act.
The list is based on reports received by H. Lundbeck A/S from the company's executives today or yesterday.
| Name: | Ulf Wiinberg |
| Job position of the executive: | President and CEO |
| ID code (ISIN code): | DK 0010287234 |
| Description of the security: | Share |
| Nature of the transaction: | Purchase of shares |
| Date of trading: | 9 August 2012 |
| Market on which the trading was effected: | Nasdaq OMX Copenhagen |
| Number of traded securities: | 7,000 shares |
| Market price of securities traded: | DKK 771,400 |
Persons or entities under an obligation to report are defined as members of the Executive Management and the Supervisory Board of H. Lundbeck A/S and persons/entities closely associated to them.
Closely associated persons/entities means inter alia:
- spouse or cohabitant
- children below the age of 18
- legal entities in which the insider has a controlling influence
The content of this release will have no influence on the Lundbeck Group’s financial expectations for 2012.
Lundbeck contacts
| Investors: | Media: |
| Palle Holm Olesen | Mads Kronborg |
| Chief Specialist, Investor Relations | Media Relations Manager |
| palo@lundbeck.com | mavk@lundbeck.com |
| +45 36 43 24 26 | +45 36 43 28 51 |
| Magnus Thorstholm Jensen | Simon Mehl Augustesen |
| Investor Relations Officer | International Media Specialist |
| matj@lundbeck.com | smeh@lundbeck.com |
| +45 36 43 38 16 | +45 36 43 49 80 |
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.
Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 6,000 people worldwide. Lundbeck is one of the world’s leading pharmaceutical companies working with brain disorders. In 2011, the company's revenue was DKK 16.0 billion (approximately EUR 2.1 billion or USD 3.0 billion). For more information, please visit www.lundbeck.com.